艾伯维杀入减重赛道 寻找下一个“药王”?

新京报
04 Mar

艾伯维还是杀入了减重赛道。美国时间3月3日,艾伯维宣布与Gubra公司达成许可协议,共同开发用于治疗肥胖症的潜在同类最佳长效胰淀素类似物,交易总额最高可达22亿美元。当前减重赛道火热,2024年两款全球畅销减重药物更是合计卖出了457.42亿美元。  自旗下修美乐因专利到期等因素销售开始下滑后,艾伯维业绩受到影响,近年来也在频频对外合作,提振业绩。  逾22亿美元入局减重赛道  根据艾伯维与...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10